A contemporary view of the treatment of allergic rhinitis patients: When standard therapy isn’t enough
Meditsinskiy sovet = Medical Council · 05.06.2026 · (6) · 70-74
DOI: 10.21518/ms2026-145 ↗Kurz gefasst
Fachartikel in der Zeitschrift Meditsinskiy sovet = Medical Council, online erschienen am 05.06.2026. Verfasst von V. M. Svistushkin und 5 weiteren Autor:innen. Die Arbeit nennt 13 Literaturangaben.
Abstract (Originalsprache)
Allergic rhinitis (AR) is one of the most common chronic diseases of the upper respiratory tract, in which a focus of inflammation forms in the mucous membrane of the nasal cavity. Pathogenetically, inflammation in the nasal cavity is caused by the development of immediate-type hypersensitivity involving IgE, the so-called T2 inflammation. The diagnosis of AR is a multidisciplinary task. The treatment of AR is a complex of measures, including elimination therapy, drug treatment and allergen-specific immunotherapy. An important aspect of the management of such patients is their training in order to manage the disease. Currently, one of the most modern areas of therapy for AR patients is the use of biological therapy, namely monoclonal antibodies. Monoclonal antibodies have proven their safety and effectiveness in the treatment of various diseases based on the results of numerous studies. The clinical recommendations of the Ministry of Health of the Russian Federation recommend the use of omalizumab for the treatment of patients with severe persistent rhinitis or severe exacerbation. The results of clinical studies have demonstrated that the addition of omalizumab to standard therapy for patients with AR is well tolerated and more effective than traditional treatment. There was a marked reduction in nasal and ophthalmological symptoms, a clinically significant improvement in quality of life and a decrease in the impact of the disease on daily activities and labor productivity. An observation of a patient presenting with AR, allergic conjunctivitis, and bronchial asthma revealed a positive clinical and functional response to genetically engineered biological therapy. This improvement was documented through validated questionnaires, detailed patient history, and comprehensive otorhinolaryngological examination.
Zitieren
APA
Svistushkin, V. M., Nikiforova, G. N., Shustrova, A. N., Mokoyan, Z. T., Rybakova, E. Y., & Bobrikova, E. N. (2026). A contemporary view of the treatment of allergic rhinitis patients: When standard therapy isn’t enough. Meditsinskiy sovet = Medical Council, 70-74. https://doi.org/10.21518/ms2026-145
Vancouver
Svistushkin VM, Nikiforova GN, Shustrova AN, Mokoyan ZT, Rybakova EY, Bobrikova EN. A contemporary view of the treatment of allergic rhinitis patients: When standard therapy isn’t enough. Meditsinskiy sovet = Medical Council. 2026:70-74. doi:10.21518/ms2026-145
BibTeX
@article{Svistushkin2026,
author = {Svistushkin, V. M. and Nikiforova, G. N. and Shustrova, A. N. and Mokoyan, Zh. T. and Rybakova, E. Yu. and Bobrikova, E. N.},
title = {A contemporary view of the treatment of allergic rhinitis patients: When standard therapy isn’t enough},
journal = {Meditsinskiy sovet = Medical Council},
year = {2026},
number = {6},
pages = {70--74},
doi = {10.21518/ms2026-145}
}
EUVIMED